Cabozantinib versus everolimus in advanced renal-cell carcinoma
Carcinoma, Renal Cell
Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy. (Funded by Exelixis; METEOR ClinicalTrials.gov number, NCT01865747.).